The possible therapeutic role of melatonin in the pathophysiology of coronary artery disorder (CAD) is increasingly being recognized. In humans, exogenous melatonin has been shown to decrease nocturnal hypertension, improve systolic and diastolic blood pressure, reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, and reduce serum catecholamine levels. Low circulating levels of melatonin are reported in individuals with CAD, arterial hypertension, and congestive heart failure. This review assesses current literature on the cardiovascular effects of melatonin in humans. It can be concluded that melatonin deserves to be considered in clinical trials evaluating novel therapeutic interventions for cardiovascular disorders.
The focus of this review article is on the therapeutic potential of melatonin in CVDs. Melatonin (IUPAC name: N-[2-(5methoxy-1H-indol-3-yl) ethyl] acetamide) is a natural methoxyindole first described as a pineal hormone and later shown to bepresent in most mammalian and nonmammalian cells. 4 Its effect is thought to be mediated through both receptormediated and receptor-independent mechanisms. The receptor-mediated actions of melatonin comprise of membrane melatonergic receptors (MT1 and MT2) located throughout the vascular system including the heart (cardiomyocytes, left ventricle, and coronary arteries). 5, 6 Melatonin may also be the natural ligand for the retinoid-related orphan nuclear hormone receptor family (RZR/ROR). 7 The MT1 melatonergic receptors mediate arterial vasoconstriction, inhibit neuronal firing and cell proliferation in cancer cells, and modulate reproductive and metabolic functions. 8, 9 Activation of MT2 melatonergic induces vasodilation, phase shift circadian rhythms of neuronal firing in the suprachiasmatic nucleus, enhances immune responses, and inhibits dopamine release in retina and leukocyte rolling in arterial beds. The receptor-independent mechanism of action of melatonin is achieved through its antioxidant and mitochondrial-protecting effects. 7 Melatonin has been shown to decrease nocturnal hypertension, 10 reduce the pulsatility index in the internal carotid artery, decrease platelet aggregation, 11, 12 and reduce serum catecholamine levels. 13 Moreover, decreased melatonin levels were reported in various pathological conditions including hypertension with nondipper pattern, 14 congestive heart failure (CHF), 15 ischemic heart disease, 16 or in patients after acute myocardial infarction. 17 Figure 1 presents the functional pleiotropy of melatonin.
This article provides a review of current literature on the cardiovascular effects of melatonin in humans. Medical literature was identified by searching databases including (MED-LINE, EMBASE), bibliographies from published literature, and clinical trial registries/databases. Searches were last updated on August 10, 2015.
Basic Aspects of Melatonin Physiology Relevant to Cardiovascular Physiopathology
By using specific melatonin antibodies, the presence of melatonin has been verified in multiple extrapineal tissues such as the brain, retina, lens, cochlea, Harderian gland, airway epithelium, gastrointestinal tract, liver, kidney, thyroid, pancreas, thymus, spleen, immune system cells, skin, carotid body, reproductive tract, and endothelial cells. 18 For further details, the reader is referred to a review by Acuña-Castroviejo et al. 18 Whether melatonin is produced in those tissues is a matter of debate because melatonin's amphiphilicity would allow an easy entry from circulation in most cases. 19 However, in some tissues, melatonin concentrations exceed those in the blood. 20 Although the enzymatic machinery to produce melatonin is found in most of these locations, 18 circulating melatonin in mammals is derived exclusively from the pineal gland.
Melatonin effects on the vasculature depend on the specific receptor type activated. Animal studies reveal that vasoconstriction is mediated through MT1 activation and vasorelaxation through MT2 activation, with the likely mechanism of action being via the modulation of the noradrenergic and/or nitric oxide (NO) effect. 21 Melatonin is metabolized in the liver to 6-sulfatoxymelatonin (aMT6s), which is subsequently excreted in urine. 22 Melatonin that is produced outside the pineal gland generally does not reach the circulation, for example, in case of the gastrointestinal tract, melatonin goes through a high presystemic hepatic elimination rate and therefore does not exert systemic effects. 23 Reactive oxygen and nitrogen species are significant contributors to cardiac damage during ischemia-reperfusion injury after an acute coronary syndrome. The reported lower serum level of melatonin in this group of individuals (Table 1) worsens the possibility of further cardiac damage from ischemiareperfusion injury because melatonin has been described as a direct free radical scavenger that protects against reactive oxygen and nitrogen species with high efficacy. 30 Melatonin also indirectly stimulates antioxidative enzymes such as superoxide dismutase, glutathione peroxidase, glutathione reductase, and glucose-6-phosphate dehydrogenase, thereby lowering molecular damage under conditions of elevated oxidative stress such as acute coronary syndrome. 30 Because of its highly lipophilic properties, melatonin crosses all cell membranes and easily reaches subcellular compartments, including mitochondria and nuclei, where it may accumulate in high amounts. 18, 31 Melatonin counteracts lipid peroxidation 32 and DNA damage. 33 In particular, melatonin preserves normal mitochondrial function by reducing and preventing mitochondrial oxidative stress, thus curtailing subsequent apoptotic events and cell death. 18, 31 Not only is melatonin itself a direct free radical scavenger but also metabolites that are formed during these interactions like N1-acetyl-N2-formyl-5-methoxykynuramine, which is deformylated to N1-acetyl-5-methoxykynuramine, and cyclic 3-hydroxymelatonin are also free radical scavengers. 34 Thus, a cascade of metabolites of melatonin may contribute to the efficacy of the parent molecule to protect against oxidative stress. 7 A major question to the view that antioxidants exert their healthprotective effects by 1-electron reactions with free radicals has been raised by Forman et al. 35 By kinetic constraints, in vivo scavenging of radicals may be ineffective in antioxidant defense. Instead, enzymatic removal of nonradical electrophiles, such as hydroperoxides, in 2-electron redox reactions could be the major antioxidant mechanism. 35 Indeed, the concept of radical avoidance was proposed to attempt to explain the protective effects of melatonin at the level of radical generation rather than detoxification of radicals already formed. 36 If melatonin is capable of decreasing the processes leading to enhanced radical formation, this might be achieved by low concentrations of the methoxyindole. The isoforms of NAD(P)H oxidases (Nox) and the mitochondria should be mentioned as main sources of free radicals. Moreover, reactive nitrogen species can secondarily give rise to the formation of reactive oxygen species (ROS), both in and outside mitochondria, so that levels of oxidants can be considerably decreased by limitation of NO formation. Melatonin downregulates NO synthesis and inhibits ROS formation in microglia exposed to amyloid-b 1-42 by preventing the phosphorylation of the p47 Nox subunit. 37 Melatonin is also very effective to attenuate mitochondrial-free radical formation. Therefore, radical avoidance by melatonin must be recognized as a highly complex phenomenon, which comprises the integrative, orchestrating role of this molecule with its numerous actions at different levels. It should be noted that concentrations of melatonin may be sufficient for relevant direct scavenging in melatoninsynthesizing organs, especially pineal gland and Harderian gland. Whether accumulation in mitochondria leads to effective concentrations may be debated but is uncertain.
Melatonin displays a significant anti-inflammatory action and reduces the serum levels of oxidized low-density 38, 39 Indeed, oxidized LDL participates in the initiation and progression of atherosclerosis and contributes to endothelial dysfunction and plaque destabilization through multiple mechanisms. 40 In vitro melatonin was found to inhibit oxidative LDL modification, 41 a process that may translate in reduced formation of atherogenic plaques in vivo. Melatonin also decreases the formation of cholesterol and reduces LDL accumulation in freshly isolated human mononuclear leukocyte. 42 However, not all studies have reported the LDLlowering effect of melatonin. 43 Cyclophilin A is a ubiquitously expressed protein that has been highlighted as a major secreted oxidative stress-induced factor in atherosclerosis. In a study evaluating the role of cyclophilin A in the early phase of atherosclerosis, the atheroprotective effect of melatonin was assessed. 44 Cyclophilin A expression increased and modulated inflammatory cell adhesion and interleukin 6 expression inducing vascular smooth muscle cell migration and inflammatory cell extravasation. All these effects were prevented by melatonin, indicating that melatonin treatment may represent a new atheroprotective approach that contributes to reducing the early phase of atherosclerosis. 45 Melatonin inhibits several physiological processes in human platelets including the aggregation phenomenon, the release of ATP and serotonin (indexes of the platelet secretory mechanism), and the production of thromboxane B2. 11, 12 In an experimental study with an isolated perfused heart model in which the anterior descending coronary artery was temporarily ligated, infusion of melatonin (1-250 mmol/L) during the ischemic and reperfusion episodes prevented the occurrence of arrhythmias including premature ventricular contraction and ventricular fibrillation, which have been shown to occur on reperfusion without the infusion of melatonin. 46 Protective effects of melatonin shortly after coronary artery ligation and in the absence of ischemia reperfusion were also reported. 47 In a recent study using genetically engineered mice, it was demonstrated that nuclear melatonin receptor RORa may serve as an endogenous defender against ischemia reperfusion injury and may mediate the beneficial effect of melatonin on myocardial ischemia and reperfusion injury. 48 Likewise, the ex vivo pretreatment with melatonin improved survival and function of adipose tissue-derived mesenchymal stem cells in vitro and in vivo, and by using a rat model of myocardial infarction, it was found that melatonin pretreatment enhanced the viability of engrafted stem cells and promoted their therapeutic potency. 49 In view of these experimental and observational cross-sectional studies, melatonin might exert a cytoprotective effect at the level of human heart.
Melatonin Levels in CVDs
Individuals with elevated LDL/cholesterol levels have been reported to have low circulating levels of melatonin, 50 and low melatonin levels have been reported in patients with CAD (Table 1 ). In an observational cross-sectional study of 15 individuals with CAD versus 10 healthy participants, melatonin was significantly lower in the patients with CAD than in the healthy controls. 16 This is consistent with analysis of data from another observational cross-sectional study, which reported that nighttime urinary aMT6s levels were significantly lower in patients with CAD than in the control group. 24 Significantly lower urinary aMT6s levels were reported in patients with unstable angina or in patients with stable angina. 25 Yaprak et al reported that patients with CAD secreted less nocturnal melatonin at 02:00, 04:00, and 08:00 hours than controls . 26 In another related study of 180 consecutive patients with a first ST-segment elevation myocardial infarction who underwent percutaneous coronary intervention within 6 hours from onset of symptoms, patients with angiographic no-reflow had lower intraplatelet melatonin levels compared to patients without noreflow. 28 Intraplatelet melatonin levels were the only significant predictor of angiographic no-reflow after adjusting for potential confounders. Low urinary aMT6s excretion was reported in CHF, a decrease that was observed regardless of b-adrenergic blocker. There were no significant differences in the low urinary aMT6s levels between patients with chronic and acute CHF. 15 Concerning patients with hypertension, there were reports indicating the suppression of nocturnal melatonin secretion in nondippers, 14, 27 and in an observational longitudinal study of 554 young women without baseline hypertension, the relative risk for incident hypertension among women in the highest quartile of urinary melatonin was about half that in the lowest quartile. 29 
Melatonin Effects on Arterial Blood Pressure in Humans
Numerous pharmacological and nonpharmacological procedures have been used in the treatment of hypertension; however, the percentage of individuals with uncontrolled hypertension still remains unacceptably high. 51 The effects of melatonin on cardiovascular function in healthy participants are significant ( Table 2 ). Melatonin in comparison to placebo was able to reduce blood pressure (BP), vascular reactivity, the pulsatility index in the internal carotid artery, and circulating catecholamines in healthy participants. 13, 52, 53 In another related study comparing postmenopausal women with and without hormone replacement therapy (HRT), melatonin reduced internal carotid artery pulsatility index, systolic and diastolic BP, and increased the NO level in HRT-treated women only, suggesting that several effects of melatonin may be modulated by gonadal steroids. 54 As shown by power spectral analysis of heart rate variability and BP monitoring, melatonin administration increased cardiac vagal tone and reduced plasma norepinephrine and dopamine levels in the supine position in awake healthy volunteers. 55 Although BP was reduced significantly, heart rate and burst rate of muscle sympathetic nerve activity (MSNA) did not change significantly after melatonin. 56 However, in another study examining the sympathetic nerve responses to orthostatic stress, the increase in MSNA was smaller in the melatonin-treated group. 57 Blunted decline in the physiological BP's nocturnal fall, the nondipper pattern, is associated with hypertension-induced organ damage such as left ventricular hypertrophy, microalbuminuria, reduced arterial compliance, and worse prognosis in terms of cardiovascular events. 58 As shown in Table 3 , melatonin treatment can be useful in this kind of patients.
A double-blind, placebo-controlled study demonstrated that melatonin given orally (2.5 mg/d) for 3 weeks to patients with essential hypertension significantly reduced both systolic and diastolic BP. 60 Nondipper hypertensives have also been found to have a missing surge of melatonin production at nighttime compared to hypertensives who had an appropriate reduction in BP at nighttime (Table 1) . 14, 27 In a meta-analysis performed on the effect of melatonin on nocturnal BP, the combination of controlled-release melatonin and antihypertensive treatment was found effective and safe in ameliorating nocturnal hypertension, whereas fast-release melatonin was not. 61 The data differed from a former report indicating that the evening administration of melatonin induced an increase of BP and heart rate in patients with hypertension well controlled by nifedipine. 59 These discrepancies underline the necessity of further studies on the matter.
It has been suggested that the reduction in nocturnal BP by repeated melatonin intake at night is attributable to its curing effect on the circadian output of the suprachiasmatic nucleus. 64 The normalization of circadian pacemaker function in the regulation of BP by melatonin treatment has thus been proposed as a potential strategy for the treatment of essential hypertension.
The vasoregulatory actions of melatonin are complex and may involve both central and peripheral mechanisms. 65, 66 The responses elicited by the activation of MT1 (vasoconstriction) and MT2 (vasodilation) are dependent on circadian time, duration, and mode of exposure to endogenous or exogenous melatonin, as well as of functional receptor sensitivity.
Potential Use of Melatonin in Pulmonary Hypertension
Oxidative stress has been proposed as one of the major mechanisms leading to the development of pulmonary hypertension. 67, 68 Therefore, it is reasonable to explore the effect of antioxidant therapy in pulmonary hypertension. As discussed above, melatonin has a potent antioxidant activity, which can reduce antioxidant damage in cardiovascular tissues.
Three recent animal studies have suggested that melatonin may be beneficial in hypoxic pulmonary hypertension. In one study performed in newborn sheep gestated, born, and raised at 3600 m, melatonin reduced pulmonary artery pressure and resistance for the first 3 days of treatment and significantly improved the vasodilator function of small pulmonary arteries, reduced pulmonary oxidative stress markers, and increased enzymatic and nonenzymatic antioxidant capacity. 69 In another study performed in Sprague Dawley rats exposed to intermittent chronic hypoxia for 4 weeks to induce hypoxic pulmonary hypertension, 70 melatonin administration attenuated the elevation of right ventricular pressure and reduced the pulmonary vascular structure remodeling. In line with these findings, a third study assessed the effect of melatonin as a curative or preventive therapy of pulmonary hypertension in Long Evans rats in which pulmonary hypertension had been induced by injecting monocrotaline. Melatonin was administered 5 days prior to or 14 days after the injection of In untreated postmenopausal women, melatonin treatment was ineffective, while in HRT-treated women, studied during the estrogenic phase, melatonin reduced, within 90 minutes, systolic (À8.1 + 9.9 mm Hg; P ¼ .054), diastolic (À5.0 + 7.0 mm Hg; P ¼ .049), and mean (À6.0 + 6.6 mm Hg; P ¼ .037) BP. Norepinephrine but not epinephrine levels were also reduced. Similarly, resistance to blood flow in the internal carotid artery was decreased by melatonin 54 Placebo-controlled study 26 healthy men Melatonin (2 mg). Power spectral analysis of heart rate variability (HRV) and BP monitoring were recorded in the supine position before and 60 minutes after melatonin administration and in the standing position 60 minutes after administration. Plasma catecholamine levels were also measured Compared with placebo, melatonin administration increased R-R interval, the square root of the mean of the squared differences between adjacent normal R-R intervals, melatonin decreased the low-frequency to high-frequency ratio and BP in the supine position (P < .01). Plasma norepinephrine and dopamine levels in the supine position after melatonin administration were significantly lower than in placebo 55 Observational study 5 healthy male participants 3 mg of melatonin was given and the BP, heart rate, and muscle sympathetic nerve activity (MSNA) were recorded continuously for 80 minutes BP was reduced significantly, while heart rate and burst rate of MSNA did not change significantly 56 Placebo-controlled study 11 healthy participants 50 minutes after receiving a 3 mg tablet of melatonin or placebo (in different days) sympathetic nerve responses to orthostatic stress (MSNA), arterial BP, heart rate, forearm blood flow, and thoracic impedance were measured During the placebo trial, MSNA increased by 33% + 8% and 251% + 70% during À10 and À40 mm Hg, respectively, but increased by only 8% + 7% and 111% + 35% during À10 and À40 mm Hg with melatonin, respectively (P < .01). Arterial BP and forearm vascular resistance responses to orthostatic stress were unchanged by melatonin 57 Abbreviations: BP, blood pressure. monocrotaline. The study showed that both curative and preventive treatment improved right ventricular functional and plasma oxidative stress parameters and reduced cardiac interstitial fibrosis. 71 Therefore, melatonin seems to confer beneficial effects in pulmonary hypertension via antioxidant, anti-inflammatory, and antiproliferative mechanisms. Clinical investigation of the effects of melatonin on right ventricle hemodynamic function in patients with pulmonary hypertension is warranted.
Melatonin Dose and Safety
The majority of clinical trials on the therapeutic usefulness of melatonin in different fields of medicine have shown very low toxicity of melatonin over a wide range of doses. 72 Doses of melatonin that considerably exceed those used in cardiovascular disorders have been found to be safe. In the treatment of amyotrophic lateral sclerosis, patients received either 60 mg/d orally for up to 13 months 73 or enteral doses of 300 mg/d for up to 2 years. 74 In a phase 1 dose escalation study in healthy volunteers to assess the tolerability and pharmacokinetics of 20, 30, 50, and 100 mg oral doses of melatonin, no adverse effects after oral melatonin, other than mild transient drowsiness with no effects on sleeping patterns, were seen. 75 Therefore, further clinical trials using dosages of melatonin in the range of 50 to 100 mg/d appear to be reasonable and are warranted. The priorities for populations, outcomes, and durations of these studies must be defined.
Conclusion
The possible therapeutic role of melatonin in CVDs is increasingly apparent, especially with potential benefits in the reduction of ischemia-reperfusion injury and decreasing nocturnal BP. The data suggest that preserving endogenous melatonin levels, or the use of melatonin supplements, may be beneficial in CVDs.
Melatonin is available in pharmacologically pure form, is relatively inexpensive, is absorbed when administered via any route, and its toxicity is remarkably low. Considering that CVDs are the leading cause of death globally, 1 the fact that melatonin has been found to be cardioprotective and possess low toxicity could have important clinical implications. Therefore, more extensive, large-size clinical trials are needed to evaluate melatonin's efficacy as a novel therapeutic intervention in CVDs.
